Healthcare entity

CBER

organization

All 1 tracked stories fall under one category: regulation. Of the tracked stories, 1 of 1 also mention FDA, the most common co-covered peer. The tracked stories average 6 original sources each. CBER appears in 1 tracked Healthcare story from March 7, 2026.

Last mentioned: Mar 7, 2026

RSS updates
Share

Entity pulse

Recent coverage · CBER

1 story
6 avg impact
0% positive
100% negative

Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.

  • 100% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about CBER

All 1 tracked stories fall under one category: regulation. Of the tracked stories, 1 of 1 also mention FDA, the most common co-covered peer. The tracked stories average 6 original sources each. CBER appears in 1 tracked Healthcare story from March 7, 2026.

Stories tracked
1
Sources per story
6

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 8 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering CBER. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Final Departure

    Official announcement of Marks leaving the agency for the second time.

  2. Initial Friction

    Reports surface of Marks considering resignation amid administrative policy shifts.

  3. Operation Warp Speed

    Plays a central role in the emergency use authorizations for COVID-19 vaccines.

  4. Appointed Director

    Promoted to Director of CBER, overseeing the 'Gold Standard' of vaccine review.

  5. Joins FDA

    Dr. Peter Marks joins the FDA as Deputy Director of CBER.

Stories mentioning CBER 1

Health Policy Negative

FDA Vaccine Chief Departs Amid Regulatory Overhaul and Political Pressure

Dr. Peter Marks, the long-serving head of the FDA’s vaccine division, is stepping down for the second time as the Trump administration intensifies its 'Make America Healthy Again' initiatives. His exit marks a critical turning point for the Center for Biologics Evaluation and Research and signals a potential shift in the agency's rigorous approval standards.

6 sources

Source: mymotherlode.com · journalgazette.net

CBER is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.